Krystal Biotech, Inc. Financials

Market Capitalization $4.46 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	87.11
Forward PE	26.51
Price to Sales TTM	$18.46
Price to Book MRQ	$5.03
Enterprise to Revenue	16.06
Enterprise to EBITDA	56.10

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	21.68%
Operating Margin	41.67%
Return on Assets TTM	4.58%
Return on Equity TTM	6.38%

Income Statement

Revenue TTM	$241,519,008
Revenue per Share TTM	$8.49
Quarterly Revenue Growth	879.90%
Gross Profit TTM	$223,536,000
EBITDA	$220,174,000
Net Income to Common TTM	$52,372,000
Diluted EPS TTM	$1.78
Quarterly Earnings Growth YoY	-66.30%

Balance Sheet

Total Cash MRQ	$588,323,968
Total Cash per Share MRQ	$20.46
Total Debt MRQ	$
Total Debt to Equity MRQ	0.84
Current Ratio MRQ	7.97
Book Value per Share MRQ	$30.81

Cash Flow

Operating Cash Flow TTM	$63,345,000
Levered Free Cash Flow TTM	$42,384,248

KRYS Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	28,760,500
Float Shares	22,925,320
Avg 10 Volume	299,530
Avg 30 Volume	None
Shares Short	3,369,689
Short Ratio	11.29
Short % of Shares	15.45%
% Held by Insiders	12.13%
% Held by Institutions	106.84%

Stock Price Summary

Beta	0.82
Fifty Two Week Low	$107.50
Fifty Two Week High	$219.34
Fifty Two Week Change	23.07%
Day 50 MA	$170.79
Day 200 MA	$177.57

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date